trending Market Intelligence /marketintelligence/en/news-insights/trending/AfwYRUYbO6CEftrg6ZmpGg2 content esgSubNav
In This List

Private equity firm Afinum buys majority stake in Swiss biotech evitria

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Private equity firm Afinum buys majority stake in Swiss biotech evitria

Private equity firm Afinum Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in Swiss biotechnology company evitria AG.

Evitria provides custom antibodies to pharmaceutical and biotech companies for research purposes.

Afinum Achte Beteiligungsgesellschaft mbH & Co. KG, advised by Afinum Management GmbH, acts as lead investor and majority owner, and jointly invests with SHS V Medtech Investments GmbH & Co. KG and management into evitria.